A new study shows that brain cancer patients treated with Peregrine Pharmaceuticals' Cotara agent experience long-term survival, the Tustin, CA, company said.
Current Cancer Therapy Reviews published data online from investigators at the Huntsman Cancer Institute at the University of Utah Medical Center and researchers at Peregrine Pharmaceuticals that support the clinical potential of Cotara for treating patients with glioblastoma multiforme (Curr Cancer Ther Rev, February 2010, Volume 6:4, pp. 13-18).
Data presented from the study, which included 28 patients, showed that seven (25%) of the 28 patients survived more than one year after treatment and three (10.7%) of the 28 have survived more than five years after treatment, including two patients who have survived more than nine years. The median survival time of the 28 patients was 38 weeks, a 58% increase over the historical median survival time of 24 weeks for glioblastoma multiforme patients treated with standard-of-care therapy, Peregrine said.
Cotara attaches a radioactive molecule to a monoclonal antibody that hones in on cells at the center of brain tumors. It is currently being tested in a phase II clinical trial in recurrent glioblastoma multiforme patients, according to Peregrine.
Related Reading
Peregrine announces 2010 Q2 results, December 10, 2009
Peregrine posts Q1 2010 results, September 3, 2009
Peregrine nets European patent, July 2, 2009
Peregrine reports healthy Q3 revenue, March 13, 2009
Peregrine mourns loss of chairman, December 11, 2008
Copyright © 2010 AuntMinnie.com
